Copper(II)-Based Nano-Regulator Correlates Cuproptosis Burst and Sequential Immunogenic Cell Death for Synergistic Cancer Immunotherapy
Biomaterials Research · 2024-01 · 28
DOI: 10.34133/bmr.0039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomaterials Research, online erschienen am 27.06.2024. Verfasst von Yingli Luo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, PR China. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Immunogenic cell death (ICD) of tumor cells serves as a crucial initial signal in the activation of anti-tumor immune responses, holding marked promise in the field of tumor immunotherapy. However, low immunogenicity tumors pose challenges in achieving complete induction of ICD, thereby limiting the response rates of immunotherapy in clinical patients. The emergence of cuproptosis as a new form of regulated cell death has presented a promising strategy for enhanced immunotherapy of low immunogenic tumors. To trigger cuproptosis, copper-ionophore elesclomol (ES) had to be employed for the copper-transporting-mediated process. Herein, we proposed a copper(II)-based metal-organic framework nanoplatform (Cu-MOF) to facilitate a cooperative delivery of encapsulated ES and copper (ES-Cu-MOF) to induce cuproptosis burst and enhance ICD of fibrosarcoma. Our results showed that the ES-Cu-MOF nano-regulator could effectively release Cu 2+ and ES in response to the intracellular environment, resulting in elevated mitochondrial ROS generation and initiated cuproptosis of tumor cells. Furthermore, sequential ICDs were significantly triggered via the ES-Cu-MOF nano-regulator to activate the anti-tumor immune response. The results of tumor inhibition experiment indicated that the nano-regulator of ES-Cu-MOF obviously accumulated in the tumor site, inducing ICD for dendritic cell activation. This enabled an increased infiltration of cytotoxic CD8 + T cells and consequently enhanced antitumor immune responses for successfully suppressing fibrosarcoma growth. Thus, the copper(II)-based metal-organic framework nano-regulator offered a promising approach for inducing cuproptosis and cuproptosis-stimulated ICD for cancer immunotherapy.
Autor:innen und Institutionen
- Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, PR China.
- Affiliated Hospital of Jiangnan University, Jiangnan University, Wuxi, Jiangsu 214062, PR China.
- Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei 230601, China.
- Joint Centre of Translational Medicine, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325000, PR China.
ORCID-Profile: Jilong Wang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Luo, Y., Luo, X., Ru, Y., Zhou, X., Liu, D., Huang, Q., Linghu, M., Wu, Y., Lv, Z., Chen, M., Ma, Y., Huang, Y., & Wang, J. (2024). Copper(II)-Based Nano-Regulator Correlates Cuproptosis Burst and Sequential Immunogenic Cell Death for Synergistic Cancer Immunotherapy. Biomaterials Research, 28. https://doi.org/10.34133/bmr.0039
Vancouver
Luo Y, Luo X, Ru Y, Zhou X, Liu D, Huang Q, et al. Copper(II)-Based Nano-Regulator Correlates Cuproptosis Burst and Sequential Immunogenic Cell Death for Synergistic Cancer Immunotherapy. Biomaterials Research. 2024;28. doi:10.34133/bmr.0039
BibTeX
@article{Luo2024,
author = {Luo, Yingli and Luo, Xianyu and Ru, Yi and Zhou, Xinru and Liu, Didi and Huang, Qian and Linghu, Maoyuan and Wu, Yuhang and Lv, Zicheng and Chen, Meimei and Ma, Yinchu and Huang, Yi and Wang, Jilong},
title = {Copper(II)-Based Nano-Regulator Correlates Cuproptosis Burst and Sequential Immunogenic Cell Death for Synergistic Cancer Immunotherapy},
journal = {Biomaterials Research},
year = {2024},
volume = {28},
doi = {10.34133/bmr.0039}
}
EUVIMED